kk jili free 58 login register
kk jili free 58 login register
Ravens claim WR/PR Steven Sims off of waivers
Middle East latest: Defense minister acknowledges Israel killed Hamas leaderIs he a hero? A killer? Both? About the same time the #FreeLuigi memes featuring the mustachioed plumber from “Super Mario Brothers” mushroomed online, commenters shared memes showing Tony Soprano pronouncing Luigi Mangione , the man charged with murdering the UnitedHealthcare CEO in Manhattan , a hero. There were posts lionizing Mangione’s physique and appearance, the ones speculating about who could play him on “Saturday Night Live,” and the ones denouncing and even threatening people at a Pennsylvania McDonald’s for spotting him and calling police. It was all too much for Pennsylvania's governor, a rising Democrat who was nearly the vice presidential nominee this year. Josh Shapiro — dealing with a case somewhere else that happened to land in his lap — decried what he saw as growing support for “vigilante justice.” People are also reading... The curious case of Brian Thompson and Luigi Mangione captivated and polarized a media-saturated nation. It also offers a glimpse into how, in a connected world, so many different aspects of modern American life can be surreally linked — from public violence to politics, from health care to humor (or attempts at it) . It summons a question, too: How can so many people consider someone a hero when the rules that govern American society — the laws — are treating him as the complete opposite? Luigi Mangione, a suspect in the fatal shooting of UnitedHealthcare CEO Brian Thompson, on Monday at the police station in Altoona, Pa. Writings found in Mangione's possession hinted at a vague hatred of corporate greed and an expression of anger toward “parasitic” health insurance companies. Bullets recovered from the crime scene had the words “deny,” “defend” and “depose,” reflecting words used by insurance industry critics, written on them. A number of online posts combine an apparent disdain for health insurers — with no mention of the loss of life. “He took action against private health insurance corporations is what he did. he was a brave italian martyr. in this house, luigi mangione is a hero, end of story!” one anonymous person said in a post on X that has nearly 2 million views. On Monday, Shapiro took issue with comments like those. It was an extraordinary moment that he tumbled into simply because Mangione was apprehended in Pennsylvania. Shapiro's comments — pointed, impassioned and, inevitably, political — yanked the conversation unfolding on so many people's phone screens into real life. “We do not kill people in cold blood to resolve policy differences or express a viewpoint,” the governor said. “In a civil society, we are all less safe when ideologues engage in vigilante justice.” But to hear some of his fellow citizens tell it, that's not the case at all. Like Bonnie and Clyde, John Dillinger, D.B. Cooper and other notorious names from the American past, Mangione is being cast as someone to admire. Luigi Nicholas Mangione is escorted into Blair County Courthouse on Tuesday in Hollidaysburg, Pa. Regina Bateson, an assistant political science professor at the University of Colorado at Boulder, has studied vigilantism, the term to which Shapiro alluded. She doesn’t see this case as a good fit for the word, she says, because the victim wasn’t linked to any specific crime or offense. As she sees it, it's more akin to domestic terrorism. But Bateson views the threats against election workers , prosecutors and judges ticking up — plus the assassination attempts against President-elect Donald Trump this past summer — as possible signs that personal grievances or political agendas could erupt. “Americans are voicing more support for — or at least understanding of — political violence,” she said. Shapiro praised the police and the people of Blair County, who abided by a 9/11-era dictum of seeing something and saying something. The commenters have Mangione wrong, the governor said: “Hear me on this: He is no hero. The real hero in this story is the person who called 911 at McDonald’s this morning." A person demonstrates Monday near the McDonald's restaurant in Altoona, Pennsylvania, where police earlier in the day arrested Luigi Nicholas Mangione, 26, in the Dec. 4 killing of UnitedHealthcare's CEO in Manhattan. Even shy of supporting violence, there are many instances of people who vent over how health insurers deny claims. Tim Anderson's wife, Mary, dealt with UnitedHealthcare coverage denials before she died from Lou Gehrig’s disease in 2022. “The business model for insurance is don’t pay,” Anderson, 67, of Centerville, Ohio, told The Associated Press . The discourse around the killing and Mangione is more than just memes. Conversations about the interconnectedness of various parts of American life are unfolding online as well. One Reddit user said he was banned for three days for supporting Kyle Rittenhouse, who was acquitted after testifying he acted in self-defense when he fatally shot two people in 2020 during protests. “Do you think people are getting banned for supporting Luigi?” the poster wondered. The comments cover a lot of ground. They include people saying the UnitedHealthcare slaying isn't a “right or left issue" and wondering what it would take to get knocked off the platform. “You probably just have to cross the line over into promoting violence,” one commenter wrote. “Not just laughing about how you don’t care about this guy.” Luigi Mangione is taken into the Blair County Courthouse on Tuesday in Hollidaysburg, Pa. Memes and online posts in support of the 26-year-old man, who's charged with killing UnitedHealthcare's CEO, have mushroomed online. Sign up for our Crime & Courts newsletter Get the latest in local public safety news with this weekly email.
(The Center Square) – Momentum is with the emerging electric vehicle industry even with many question marks surrounding energy policy as the Trump administration takes office in January, observers of the industry say. “At the local and state level, there's an incredible amount of energy and action taking place to support transportation electrification,” Ben Prochazka, executive director of the Electrification Coalition, told The Center Square. With Elon Musk, CEO of Tesla Motors, playing a significant role in President-elect Donald Trump’s election and chosen with Vivek Ramaswamy to head his new Department of Government Efficiency, it is also unlikely that the electric vehicle industry will be neglected nationally. “The hope is that Elon Musk has influence in the new administration, which does look to be the case,” said Prochazka. “Hopefully, that means there’s a great recognition around the economic benefits that exist.” It remains to be seen how electric vehicle incentive or tax credit programs – different than mandates – might be affected by Trump’s moves to cut spending. Mainstream outlets have already proclaimed that Trump has an "anti-EV agenda," as a group of automakers urged him to retain a national $7,500 consumer tax credit for electric vehicle purchases. On the other hand, Prochazka said tariffs and the deregulation of the domestic automotive industry could play a positive role in the electric vehicle industry, depending on how they are "established." “With any new administration, there's always going to be question marks about what the prevailing winds are,” explained Prochazka, whose nonpartisan, nonprofit coalition engages in policy development, advocacy campaigns and consumer education. "E verything has the potential to be reevaluated and then changed." Willett Kempton is in the University of Delaware's Department of Electrical and Computer Engineering and has research interests in offshore wind power, electric vehicles and public environmental beliefs and values. He agrees with Prochazka that a lot is still up in the air about Trump’s policy approach to the electric vehicle industry. Certain policies could potentially " slow down" growth domestically, he said. Yet, that wouldn't permanently stop growth. “National governments can slow this growth by policy changes, but that doesn’t change the cost advantages nor the long-term trends,” Kempton told The Center Square. In the past, Republicans generally have been notably skeptical about electric vehicles and especially mandates for them, preferring those powered by fossil fuels. Reliability is among the key drivers of the party's choice when it comes to opposition of the broader green agenda of Democrats. Musk’s involvement has the potential to change that skepticism. Prochazka said he is hopeful for that, emphasizing that his organization believes that electric vehicles should not be a partisan issue. “The last election ultimately created more partisan views on electrification,” he said. “We are working really hard to make sure it's clear that transportation electrification is not a red or a blue issue, but it's really about what's better for the country, especially when you look at it through the lens of global competition. We need to maintain our automotive leadership.” For Prochazka, growing the eclectic vehicle industry is an issue of both “national and economic security.” “The automotive sector is a trillion dollar a year industry that has millions and millions of jobs that are a part of the U.S. automotive sector," he said. "So, as the world goes electric, we need to compete so that we can not only maintain our current market share, but hopefully grow it. There’s a global race to electrification.” There are nearly 2.5 million electric vehicles registered throughout the nation, with the highest percentage of those in California. Even then, only 2.5% of the vehicles in California are electric vehicles and only 6.8% of the vehicles sold nationwide in 2024 were electric. Kempton and Prochazka say the transition to electric vehicles will be inevitable and that America should be the nation leading it. “The shift to electric vehicles is worldwide and there are so many advantages to EVs that this will proceed,” Kempton said. “In most territories, clean energy is already the lowest-cost electricity source and largest amount of new generation being installed. These are driven by market forces and producer projections of where the most future growth will be. So, I would not call these ‘movements’ but rather markets or growth trends and adoption of new technologies.” Only 38% of United States adults say they would even consider buying an electric vehicle. Prochazka said he believes that will continue to change, both as there are nationally moves to protect the economic interests of the United States and as more people get familiar with electric vehicles. “We need to also make sure the U.S. is moving as quickly as possible, so that we can compete with the sort of global efforts to electrify,” he said. “Most people have not gotten behind the wheel and have not plugged one in. I think it’s something that people really just need to try, because then they'll realize this is a much better vehicle. It's just about getting people behind the wheel.”A Utah Corrections officer who left his K-9 Loki in a parked police car for more than three hours on a hot July day last year, killing the dog, will not face criminal charges, Salt Lake County prosecutors announced Friday. K-9 Loki’s death didn’t warrant charges against his handler, officer Jacob Lee Naccarato, because prosecutors ultimately deemed it a “profoundly unfortunate accident,” District Attorney Sim Gill wrote in a finding letter released Friday. However, Gill added that prosecutors “believe that Loki’s death could — and should — have been avoided,” according to the letter. “Where human error is anticipated, it is upon us as institutions to safeguard against that error,” Gill wrote. Apparently, he said, Utah Department of Corrections officials were aware of the potential for a dog to die like Loki did, and had installed K-9 heat alert systems in this vehicle. But, the investigation found, the system wasn’t turned on and employees had not been trained in how to use it. Since Loki’s death , the department said it has implemented the technology and has created new policies meant to keep K-9s safe. (Utah Department of Corrections) Loki, an 8-year-old Belgian shepherd, worked as a K-9 with the Utah Department of Corrections until he was found dead Thursday, July 13, 2023. “We are devastated about the loss of Loki,” said Glen Mills, Corrections communications director. “It was a mistake that could have been prevented. We realize that and take responsibility for that, and it’s really important for us to learn from this and make sure that it never happens again.” Naccarato, who placed on administrative leave after Loki’s death, declined to be interviewed by investigators and did not give them a statement, the letter said. He still works at the department, Mills said, but no longer handles K-9s — “and there are no plans for him to have one anytime soon.” Now that the criminal investigation has concluded, Mills said the department will begin its own internal review of Loki’s death. He said it’s unclear how long that investigation will take. What happened to Loki On July 13, 2023, Naccarato retrieved Loki from his kennel at the Utah State Correctional Facility around 2:30 p.m. so the dog could search a warehouse at the prison. Loki finished the search, and Naccarato put the dog back in the running police vehicle at 3:02 p.m. Naccarato and another officer then went back inside to search the building, according to a news release. They returned to the car and arrived back at the kennel building at 3:12 p.m. Both officers went inside to store their vests and bags, but left Loki in the car. This time, prosecutors found, the car was turned off. The officers later left the building on foot, but returned around 3:32 p.m. to retrieve their equipment, “after being alerted to an incident that later resolved itself.” Loki remained in the car. At 3:44 p.m., the officers left in a different vehicle with a third officer to find a “missing tool” at the warehouse they had searched earlier. They returned at 6:30 p.m. About 15 minutes later, Naccarato went to grab Loki from his kennel and discovered the dog was not inside, according to Gill’s letter. Naccarato ran outside to check the car, and found Loki still inside, dead. Temperatures that day reached as high as 97 degrees and the vehicle was not parked in the shade. A necropsy found that Loki likely died of heatstroke. New K-9 safeguards Before Loki’s death, Corrections procedures were to remove dogs from vehicles when the officer was at home or in the K-9 building on the prison campus. Otherwise, the dogs could remain in the vehicle when officers are on-duty responding to issues, the letter read. The car was to remain on when the dog is inside. The Department of Corrections has since made changes, including implementing the heat alert system and trainings its officers to use it. Officers will now undergo annual training on the technology, as well, Mills said, and must carry a pager that will alert them if the system detects temperatures that are too high. The department has also changed policy so that K-9s can only travel in vehicles equipped with the heat alert technology. The vehicle must remain running at all times, and K-9s must be removed from cars after all calls for service. If a dog remains in a car during a call, an officer must check on it every 15 minutes. Handlers must also verify the dog is not in a vehicle after it has been turned off. Mills said K-9s are an important part of Corrections operations, and play a “key role in maintaining security” by sniffing out drugs and other contraband at the prison. Loki started working at the Corrections department in 2017 and helped with drug detection and catching fugitives, according to a news release. He was an 8-year-old Belgian Malinois. (Trent Nelson | The Salt Lake Tribune) The Utah State Correctional Facility in Salt Lake City on Friday, Sept. 6, 2024.
Somewhere over the rainbow there exists a magnificent movie version of Gregory McGuire’s 1995 wonderfully revisionist, not to mention delightfully feminist, fantasy novel “Wicked.” Alas, Jon M. Chu’s big, bland, and bloated journey through the glittering land of Oz is not it, my pretties. The two-part, $320 million film adaptation thoroughly lacks the pluck and spirit of the blockbuster Broadway musical, which made its debut in San Francisco in 2003. As a longtime theater critic, I hate to pour a bucket of water on this almost-three-hour movie adaptation. But despite its undeniable star power. this empty-headed screen adaptation melts in the imagination. Pop singer Ariana Grande does indeed sparkle as Galinda, the soon-to-be Good Witch, and she’s certainly a superb hair flipper, but she lacks sassiness and there’s zilch chemistry between her and the green goddess Elphaba (Cynthia Erivo) as two college frenemies who grow into the mythical witches of lore. Erivo is suitably likable as the hated Elphaba but there’s no sign of a formidable power lurking within. A lot of the plucky numbers sputter. Grande’s cutie-pie wardrobe is a real stunner, a cheeky cross between Elle Woods style and Barbie couture that fills you with an inexplicable and deep yearning to wear more pink. For all the film’s weaknesses, Paul Tazewell’s gorgeous costumes are so sharply on point they draw blood. Let’s not even talk about Glinda’s obsession-worthy assortment of shoes. The feminism may fall flat here but the fashion truly soars to new heights. Many a stocking will surely be stuffed with “Wicked” bling this Christmas. For the record, the campy cameo spotlighting Kristin Chenoweth and Idina Menzel, the original marquee stars, only serves to remind us how much their deeply-felt camaraderie buoyed the musical back in the day. Those two Broadway divas had a visceral girl-power vibe that almost made you jealous of their BFF bond, onstage and off. Their buoyant chemistry is much missed here. It should be noted that this Fiyero, the delish Jonathan Bailey, of “Bridgerton” fame,” looks as dashing as ever astride a horse and that’s no small delight. Bailey also seems more adept with a song and dance number than some of the other stars here. He imbues “Dancing through Life” with an elan and effortlessness that makes some of the other musical interludes, such as pithy hit “Popular,” come off as a tad forced. The labyrinthian revolving library set (production designer Nathan Crowley outdoes himself), which takes a page from the Hogwarts aesthetic, is also a dazzler. Sadly, however, the stalwart Michelle Yeoh, who seems like such inspired casting as Madame Morrible, the haughty headmistress of Shiz University, gets thoroughly overshadowed here and the estimable Jeff Goldblum, who should be stealing the show, as the suitably smarmy snake oil peddler turned politician, his wonderful Ozness himself, doesn’t have that much to do in the lumbering part one. Chu seems to be going for a sense of existential ennui when a good old-fashioned shake-the-rafters mood would be more fitting. It’s also unfortunate that the sluggish pacing undercuts the cautionary tale here. Look past the flying monkeys and malapropisms and there is a chilling warning about the danger of charlatans who seize political power by stoking bigotry and eroding civil rights until all but the bravest are scared into silence. L. Frank Baum’s classic 1900 fable has sharper special and political resonance now than ever before. Pay no attention to the man behind the curtain, indeed. Perhaps the movie would cast a more bewitching spell if it weren’t dragged out into two parts. The first installment ends just as Elphaba is coming into her power, in a duly high-flying “Defying Gravity” interlude, and before any real romance can blossom. Stretching out the Broadway narrative to twice its length, while adding no discernible depth, casts the film’s flaws into high relief. The irresistible pacing and tempo that powered the stage musical have all but vanished. Die-hard “Wicked” fans may not mind but casual YA fantasy fans, like my 14-year-old, may well miss what all the fuss is about. To be sure, the real magic here comes from the marvelous special effects. Chu, deservedly beloved for “Crazy Rich Asians,” creates a glittering visual fantasia that delights the eye, from the splashy underwater wonders of the ballroom to the glittering turrets of Emerald City, but often leaves the heart and mind rather bored. Lest you think I’m far too jaded to judge this “Wicked” because I’m old enough to remember the 2003 world premiere, suffice to say my kiddo was also less than impressed by the cinematic spectacle and has informed me that she will not be accompanying me for Part 2. I’ll have to ease on down the road without her. Contact Karen D’Souza at karenpdsouza@yahoo.com.
Palvella Therapeutics to debut on Nasdaq under the ticker symbol “PVLA” as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic diseases Strong balance sheet with approximately $80.0 million of cash and cash equivalents, including proceeds from a PIPE financing co-led by BVF Partners, L.P. and Frazier Life Sciences Cash expected to fund operations into the second half of 2027, including through Phase 3 SELVA clinical trial of QTORINTM 3.9% rapamycin anhydrous gel (QTORINTM rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) and Phase 2 clinical trial in cutaneous venous malformations (cutaneous VMs) Microcystic LMs is a chronically debilitating and lifelong genetic disease affecting an estimated more than 30,000 diagnosed patients in the U.S. QTORINTM rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic LMs and cutaneous VMs WAYNE, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the completion of its previously announced merger with Pieris Pharmaceuticals, Inc. (Pieris). The combined company will operate under the name Palvella Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq Capital Market on December 16, 2024, under the ticker symbol "PVLA". Palvella will continue to be led by Wes Kaupinen, its Founder and Chief Executive Officer, and other members of the Palvella management team. The transaction was approved by Pieris stockholders at a special meeting held on December 11, 2024, and the transaction had been previously approved by Palvella stockholders. "With strong support from leading healthcare-dedicated investors, Palvella is well positioned to enter the public markets and pursue our vision of becoming the leading rare disease company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases," said Mr. Kaupinen. “This transaction will enable us to accelerate late-stage development of QTORINTM rapamycin, our lead product candidate, for microcystic LMs and cutaneous VMs while also further advancing additional novel product candidates from our QTORINTM platform." Concurrent with the merger, Palvella completed a previously announced oversubscribed $78.9 million private placement co-led by BVF Partners, L.P., an existing investor, and Frazier Life Sciences, a new investor, and with participation from a syndicate of leading healthcare-dedicated investors. Additional new investors include Blue Owl Healthcare Opportunities, Nantahala Capital, DAFNA Capital Management, ADAR1 Capital Management, and a healthcare dedicated fund. Existing investors Samsara BioCapital, Petrichor, CAM Capital, Ligand Pharmaceuticals, Integrated Finance Group (an AscellaHealth partner company), BioAdvance, and Gore Range Capital also participated in the financing. Palvella's cash and cash equivalents of approximately $80.0 million is expected to fund operations into the second half of 2027, including through results from the SELVA Phase 3 clinical trial of QTORINTM rapamycin for the treatment of microcystic LMs and Phase 2 clinical trial of QTORINTM rapamycin in cutaneous VMs. Palvella’s research team developed QTORINTM, a patented and versatile platform designed to generate novel topical therapies that penetrate the deep layers of the skin to locally treat a broad spectrum of serious, rare genetic skin diseases. Well-accepted mechanisms of action of rapamycin and other therapeutic agents represent potential therapies for rare genetic skin diseases. However, the adverse event profile of those agents through systemic exposure poses significant barriers to patient adoption. Palvella’s QTORINTM product candidates are designed for targeted, localized delivery of therapeutic agents to pathogenic tissue of interest while minimizing systemic absorption and thereby reducing the risk of unwanted adverse events associated with systemic therapy. Palvella's lead product candidate QTORINTM rapamycin is a novel, patented 3.9% rapamycin anhydrous gel currently under development for the treatment of microcystic LMs, cutaneous VMs, and other serious, functionally debilitating skin diseases driven by the overactivation of the mammalian target of rapamycin (mTOR) pathway. QTORINTM rapamycin has received FDA Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation for microcystic LMs and is the recent recipient of up to a $2.6 million FDA Orphan Products Grant. QTORINTM rapamycin has also received Fast Track Designation for venous malformations. QTORINTM rapamycin is protected by issued composition patents covering anhydrous gel formulations of rapamycin, as well as methods of use, in the U.S., Japan, Australia, China and Israel and pending patent applications broadly covering anhydrous gel formulations of rapamycin, as well as methods of use, in the U.S. and other countries. In the third quarter of 2024, Palvella initiated SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORINTM rapamycin administered once daily for the treatment of microcystic LMs. The primary efficacy endpoint is the change from baseline in the overall microcystic LM Investigator Global Assessment (mLM-IGA) at week 24. The Phase 3 study is enrolling approximately 40 subjects, age six or older, at leading vascular anomaly centers across the U.S. Transaction Details Based on the final exchange ratio of approximately 0.30946 shares of Pieris common stock for each share of Palvella common stock, at the closing of the merger, there are approximately 13.95 million shares of the combined company's common stock outstanding on a diluted basis, with prior Pieris stockholders owning approximately 11% on a diluted basis and prior Palvella stockholders (including investors in the private placement) holding approximately 89% of the combined company's outstanding common stock on a diluted basis. In connection with the closing of the merger, Pieris issued a non-transferable contingent value right (CVR) to Pieris shareholders of record immediately prior to the closing, which does not include the former holders of shares of Palvella or the private financing investors. Holders of the CVR will be entitled to receive payments from proceeds received by the combined company, if any, under Pieris' existing partnership agreements with Pfizer and Boston Pharmaceuticals, in addition to other potential licensing agreements involving certain of Pieris' legacy assets, as well as certain potential payments related to historical research and development tax credits, which may or may not be realized. TD Cowen served as lead placement agent and Cantor served as a placement agent for Palvella's concurrent financing. Troutman Pepper Hamilton Sanders LLP served as legal counsel to Palvella. Cooley LLP served as legal counsel to the placement agents. Stifel served as the exclusive financial advisor to Pieris and Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. served as legal counsel to Pieris. About Microcystic Lymphatic Malformations Microcystic LMs are a rare, chronically debilitating genetic disease caused by dysregulation of the phosphatidylinositol 3-kinase (PI3K)/mTOR pathway. The disease is characterized by malformed lymphatic vessels that protrude through the skin and persistently leak lymph fluid (lymphorrhea) and bleed, often leading to recurrent serious infections and cellulitis that can cause hospitalization. The natural history of microcystic LMs are persistent and progressive without spontaneous resolution, with symptoms generally worsening during life, including increases in the number and size of malformed vessels that lead to complications and lifetime morbidity. There are currently no FDA-approved treatments for the estimated more than 30,000 diagnosed patients with microcystic LMs in the United States. About Palvella Therapeutics Founded and led by rare drug disease drug development veterans, Palvella Therapeutics (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORINTM platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORINTM 3.9% rapamycin anhydrous gel (QTORINTM rapamycin), is currently in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations (microcystic LMs) and a Phase 2 trial in cutaneous venous malformations. For more information, please visit www.palvellatx.com or follow the Company on LinkedIn. QTORINTM rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency. This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (Securities Act)). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Palvella and Pieris, as well as assumptions made by, and information currently available to, management of Palvella and Pieris. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements include, but are not limited to, the sufficiency of the combined company’s capital resources; the combined company’s cash runway; the expected timing of the closing of the proposed transactions; statements regarding the potential of, and expectations regarding, Palvella’s programs, including QTORINTM rapamycin, and its research-stage opportunities, including its expected therapeutic potential and market opportunity; the expected timing of initiating, as well as the design of Palvella’s Phase 2 clinical trial of QTORINTM rapamycin in cutaneous venous malformations. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the limited operating history of each company; the significant net losses incurred since inception; the ability to raise additional capital to finance operations; the ability to advance product candidates through preclinical and clinical development; the ability to obtain regulatory approval for, and ultimately commercialize, Palvella’s product candidates, including QTORINTM rapamycin; the outcome of early clinical trials for Palvella’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; the fact that data and results from clinical studies may not necessarily be indicative of future results; Palvella’s limited experience in designing clinical trials and lack of experience in conducting clinical trials; the ability to identify and pivot to other programs, product candidates, or indications that may be more profitable or successful than Palvella’s current product candidates; the substantial competition Palvella faces in discovering, developing, or commercializing products; the negative impacts of the global events on operations, including ongoing and planned clinical trials and ongoing and planned preclinical studies; the ability to attract, hire, and retain skilled executive officers and employees; the ability of Palvella and Pieris to protect their respective intellectual property and proprietary technologies; reliance on third parties, contract manufacturers, and contract research organizations. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in Pieris’ most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC, as well as the registration statement on Form S-4 filed with the SEC by Pieris in connection with the merger. Palvella and Pieris can give no assurance that the conditions to the proposed transactions will be satisfied. Except as required by applicable law, Palvella and Pieris undertake no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release. Palvella Therapeutics Contact Information Investors Wesley H. Kaupinen Founder and CEO, Palvella Therapeutics wes.kaupinen@palvellatx.com Media Stephanie Jacobson Managing Director, Argot Partners palvella@argotpartners.com
Swiss National Bank decreased its holdings in shares of GXO Logistics, Inc. ( NYSE:GXO – Free Report ) by 0.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 233,313 shares of the company’s stock after selling 1,500 shares during the quarter. Swiss National Bank owned approximately 0.20% of GXO Logistics worth $12,149,000 at the end of the most recent reporting period. A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GXO. Eminence Capital LP bought a new stake in shares of GXO Logistics during the 2nd quarter worth about $79,698,000. Swedbank AB bought a new stake in shares of GXO Logistics during the first quarter worth approximately $84,672,000. Spruce House Investment Management LLC grew its position in shares of GXO Logistics by 827.8% in the second quarter. Spruce House Investment Management LLC now owns 900,000 shares of the company’s stock valued at $45,450,000 after purchasing an additional 803,000 shares during the last quarter. American Century Companies Inc. increased its stake in shares of GXO Logistics by 25.2% during the second quarter. American Century Companies Inc. now owns 3,221,818 shares of the company’s stock worth $162,702,000 after purchasing an additional 648,547 shares during the period. Finally, Fort Pitt Capital Group LLC lifted its holdings in GXO Logistics by 30.4% during the 2nd quarter. Fort Pitt Capital Group LLC now owns 2,416,606 shares of the company’s stock worth $122,039,000 after purchasing an additional 563,057 shares during the last quarter. 90.67% of the stock is owned by institutional investors. Wall Street Analysts Forecast Growth Several research analysts have weighed in on GXO shares. Citigroup initiated coverage on GXO Logistics in a research report on Wednesday, October 9th. They set a “buy” rating and a $60.00 price objective on the stock. Susquehanna dropped their price objective on shares of GXO Logistics from $75.00 to $73.00 and set a “positive” rating for the company in a research note on Thursday, September 26th. TD Cowen increased their target price on shares of GXO Logistics from $82.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Barclays lifted their price target on shares of GXO Logistics from $55.00 to $60.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 13th. Finally, UBS Group increased their price target on GXO Logistics from $66.00 to $72.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $67.00. GXO Logistics Price Performance GXO Logistics stock opened at $60.47 on Friday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.86 and a current ratio of 0.86. GXO Logistics, Inc. has a 52 week low of $46.07 and a 52 week high of $63.33. The stock has a market capitalization of $7.23 billion, a P/E ratio of 67.19, a price-to-earnings-growth ratio of 1.81 and a beta of 1.55. The stock has a fifty day moving average of $57.06 and a 200-day moving average of $52.70. GXO Logistics ( NYSE:GXO – Get Free Report ) last posted its earnings results on Monday, November 4th. The company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.01. The firm had revenue of $3.16 billion during the quarter, compared to analysts’ expectations of $3.01 billion. GXO Logistics had a net margin of 0.97% and a return on equity of 10.03%. The business’s revenue for the quarter was up 27.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.69 earnings per share. On average, sell-side analysts expect that GXO Logistics, Inc. will post 2.77 earnings per share for the current fiscal year. GXO Logistics Profile ( Free Report ) GXO Logistics, Inc, together with its subsidiaries, provides logistics services worldwide. The company provides warehousing and distribution, order fulfilment, e-commerce, reverse logistics, and other supply chain services. As of December 31, 2023, it operated in approximately 974 facilities. The company serves various customers in the e-commerce, omnichannel retail, technology and consumer electronics, food and beverage, industrial and manufacturing, consumer packaged goods, and others. Recommended Stories Receive News & Ratings for GXO Logistics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GXO Logistics and related companies with MarketBeat.com's FREE daily email newsletter .
Kobe Sanders, Nevada beat Oklahoma St. for fifth place in Charleston
Jeeno Thitikul has a $4M finish to win LPGA finale and Maverick McNealy wins first PGA Tour titleStudents from Indian Trail High School and Academy and Bullen Middle School volunteered stocking the Shalom Center Pantry on Friday. Their service was part of DjMr262’s week of giving in which students have been volunteering throughout the community at various sites. The week’s events, presented by Carey Norris, also known as DjMr262, continued Saturday with a bowling fundraiser and on Sunday with the annual free community dinner from 4-6 p.m. at the Shalom Center. Bullen Middle School student Katie Shumate, 15, and Bullen special education teacher Brandon Burries help stock the shelves at the Shalom Center Pantry, 4314 39th Ave., on Friday as part of DjMr262’s week of giving. Indian Trail High School and Academy students Navaeh Williams, left background, and Chloe Gant, both 15, help stock the shelves at the Shalom Center Pantry, 4314 39th Ave., on Friday as part of DjMr262’s week of giving. The 98th Macy's Thanksgiving Day Parade coverage is slated from 8:30 a.m. to 12 p.m. EST Thursday, Nov. 28. This year's event will feature 28 clown crews, 26 floats, 16 giant balloons, 11 marching bands, five performance groups, three "baloonicles"—cold-air inflatables driven down the parade route, and numerous performers. Stacker curated a selection of photographs from the past century of the Macy's Thanksgiving Day Parade to help illustrate the history of the iconic event. The parade in New York City, presented by department store chain Macy's, was first held in 1924 under the heading "Macy's Christmas Parade" to promote holiday sales and spotlight the newly expanded and, at the time, largest in the world Herald Square store in Manhattan. The success of the event led organizers to turn the spectacle into an annual tradition. Each year, the parade ends outside the same Herald Square Macy's location. The event has been televised nationally since 1953 on NBC. The parade at first featured Central Park Zoo animals escorted by Macy's employees and professional entertainers for 6 miles from 145th Street in north Manhattan's Harlem to Macy's. A quarter of a million onlookers lined the streets. Real animals were replaced with balloons in 1927; that same year, the name of the event was changed to Macy's Thanksgiving Day Parade. The longest-running parade float is the event's unofficial mascot, Tom Turkey. Tom features moving wings, head, and eyes and usually functions as the lead float in the parade. Bringing up the caboose in virtually all the parades is Santa Claus who ushers in the holiday shopping season with his arrival at Macy's Herald Square. The parade offers a glimpse into pop culture of the time, from beloved children's entertainment to hit Broadway shows and musical acts. The Radio City Rockettes, formed in 1925, have performed in the parade annually since 1957. In 1933, the outside temperature was 69 degrees F, the warmest it's been; 2018 was the coldest day in parade history at 19 degrees F. In 2022, for the first time, the event featured a trio of women hosts. Today, more than 44 million people tune in to watch the parade. Keep reading to learn more about the parade's history and see some iconic shots of the event. You may also like: Game on: The booming growth of online gaming The large balloons that replaced live zoo animals in 1927 were filled with regular air and had no release valves—they were simply let go to pop in the air following the parade. 1928 marked the first year of Macy's inflating balloons with helium to allow them to float. They were also outfitted with valves so the helium could gradually escape rather than waiting for the balloon to inevitably pop, and featured a return address so anyone who found them could return them and receive a reward. In this photo from 1928, a 35-foot fish and 60-foot-long tiger were featured prominently in the parade. A $100 prize was offered for each balloon recovered after its release. The Thanksgiving parade enjoyed rapid growth throughout the 1930s, with more than 1 million revelors lining the parade route in 1933. In this 1931 photo, a giant hippopotamus balloon makes its way down Broadway. A blue hippo balloon—possibly this one—released after the parade was still at large several days later, thought to be somewhere over the Atlantic Ocean. Pinnochio, Tin Man, and Uncle Sam make their way along the parade route in 1939. Mickey Mouse made his debut five years earlier with a balloon designed in part by Walt Disney; Mickey's handlers were also dressed as mice. New iterations of Mickey appeared over the next 70 years as the character evolved. The Macy's Thanksgiving Day Parade was canceled from 1942-1944 because of supply shortages during World War II, namely helium and rubber. Festivities returned in 1945. The Christmas classic "Miracle on 34th Street" was released in 1947 and prominently features actual footage from the 1946 parade. 1948 marked the parade's first network television broadcast. You may also like: Legendary interior designers from every decade of the 20th century The 23rd annual Macy's Thanksgiving Day Parade was held Nov. 24, 1949. In this photo, a teddy bear makes its way through Times Square. This parade marked the second appearance for the bear. Other balloons made their debut: Freida the Dachshund, Howdy Doody on the Flying Trapeze, and Macy's Hobo Clown. Macy's original character The Giant Spaceman made his debut in 1952's parade, measuring 70 feet long and 40 feet wide and weighing 600 pounds. More than 25 gallons of paint went into painting the astronaut. An estimated 2.25 million people lined the streets for the festivities that year. Throngs of onlookers pack the sidewalks in Manhattan's Times Square during this 1955 parade. Mighty Mouse, an animated superhero created by Terrytoons, is seen in the back left of the photo. Mighty Mouse made his debut in the Thanksgiving Day parade in 1951; he appeared in 80 short films between 1942-1961. The iconic peacock float makes its debut in this photo of the 1961 Macy's Thanksgiving Day Parade. That same year, Miss Teenage America Diane Lynn Cox appeared in princess attire sharing a float with "Prince Charming" actor Troy Donahue. You may also like: Baltimore buried its urban streams—now an artist is bringing one back Teen performers appear in classic roller skates in this image from the 1961 Macy's Thanksgiving Day Parade. The sign above the skaters reads "Macy's presents A Fantasy of Christmas in New York." This 1961 photo shows shoulder-to-shoulder parade onlookers at the Macy's Thanksgiving Day Parade. The year marks the first balloon featuring Bullwinkle Moose and the first year for floats with Pinocchio, The Racetrack Grandstand, Cinderella, Peacock, Ferris Wheel, Brigadoon, Meet the Mets, and Santa's Sleigh. Several years later, in 1968, Macy's creative team figured out how to design floats up to 40 feet tall and 28 feet wide that could fold into 12.5-by-8-foot boxes for strategic transportation from New Jersey to Manhattan via the Lincoln Tunnel. A Bullwinkle Moose balloon floats down Broadway in this 1972 photograph of the parade. The 46th annual parade featured five firsts for floats: Alphabet Blocks, Snow Mountain, Windmill, Curious George, and Santa's Holiday Home. Woody Woodpecker greets the crowd as he floats past One Times Square during the 63rd annual Macy's Thanksgiving Day Parade in 1989. In the coming years, safety concerns troubled '90s-era parades—namely the wind. Strong gusts in 1993 pushed a Sonic the Hedgehog balloon into a Columbus Circle lamppost that broke and hurt a child and off-duty police officer. Four years later, intense winds caused a Cat in the Hat balloon to hit a lamppost, hurling debris into the air that fractured the skull of a spectator who spent 24 days in a coma. The incident, among others, led then-New York City Mayor Rudy Giuliani to form a task force. The Soaring Spirit Canoe float, pictured here in 1995, made its debut in the parade in 1986. Popular '90s balloons included Bart Simpson, Cat in the Hat, and The Rugrats. New York City first responders carry two American flags during the Nov. 22, 2001, 75th Anniversary of Macy's Thanksgiving Day Parade, which was also held on the heels of 9/11. They honored those killed in the Sept. 11 terrorist attacks that year. New Yorkers crowded the streets to watch the parade, which featured 15 giant balloons and marching bands that all added an air of patriotism to the event. In this 2016 photo, spectators like this one recorded videos of the parade on their phones. More than 24 million people were estimated to have streamed the parade that year on TV. The Pikachu balloon floats down Central Park West for its fourth time during the 91st annual Macy's Thanksgiving Day Parade in 2017. That year's lineup featured 1,100 cheerleaders and dancers, more than 1,000 clowns, 28 legacy balloons, 26 floats, 17 giant helium balloons, 12 marching bands, and six performance groups. Performers in this photo prepare at the 94th annual Macy's Thanksgiving Day Parade on Nov. 26, 2020. The event was one of few public occasions to be kept on schedule during the COVID-19 pandemic, albeit in a tempered manner. Much of the performances were pre-taped and the parade route was massively reduced. Participants wore masks and balloon handlers were cut by nearly 90%. Santa Claus celebrates at the 97th annual Macy's Thanksgiving Day Parade in this photo from Nov. 23, 2023. First-time giant balloons included Beagle Scout Snoopy, Leo (Netflix), Monkey D. Luffy, Po from "Kung Fu Panda," and The Pillsbury Doughboy. Copy editing by Lois Hince. You may also like: From the Roman Empire to your therapist's office: The history of the chaise lounge In Macy's first Thanksgiving parade, Santa Claus sat atop a float pulled by a team of horses down Broadway. That year floats, bands, and Central Park Zoo animals were featured in the procession. At the parade's end, Santa Claus was crowned "King of the Kiddies" on Macy's balcony at the 34th Street entrance. Macy's quickly announced the parade would be an annual event. In this image, the Felix the Cat balloon is led down Broadway by its four handlers tailed by Terrible Turk and Willie Red Bird. The original Felix the Cat character balloon made its parade debut in 1927, but was destroyed after its post-parade release by a high tension wire in 1931. The Terrible Turk also was destroyed the same year by an electric sign. In 1932, Macy's Tom Cat balloon got stuck in the propeller of a plane when the aviator flying the plane tried recovering the balloon for a reward. While the plane eventually landed safely, that event marked the final year of releasing balloons after the parades and offering prizes for their return to Macy's. Subscribe to our Daily Headlines newsletter. Reporter {{description}} Email notifications are only sent once a day, and only if there are new matching items.
Scottish international Adams scores long-range stunner in Serie A win for TorinoThe rapid expansion of digital lending has also raised concerns about market stability, consumer protection, and systemic risk. Key regulatory components in digital lending includes consumer protection, data privacy and security, and licensing among others Governments can develop more adaptive, tech-friendly frameworks that promote growth while ensuring compliance through partnerships between regulators and fintech companies In the past few years, digital lending platforms have emerged as a game-changer in the financial sectors of emerging markets, offering unprecedented access to credit for underserved populations. Leveraging technology, these platforms streamline loan processes, providing speed, convenience, and inclusivity in economies where traditional banking systems often fall short. The rapid expansion of digital lending has also raised concerns about market stability, consumer protection, and systemic risk. Thus, regulatory frameworks have become crucial in shaping the future of digital lending, striking a balance between innovation and maintaining a secure, transparent financial environment. Increasing smartphone penetration, widespread internet access, and the rise of fintech innovations have contributed to the growth of digital lending in emerging markets. Adoption rates have surged as consumers seek faster, more accessible alternatives to traditional banking services, especially in regions with limited financial inclusion. Beyond convenience, innovations such as AI-driven credit scoring, blockchain-based loan agreements, and mobile wallet integration have fuelled this growth by offering secure, personalised lending solutions. Key drivers of this expansion include the growing demand for microloans, the rise of small and medium-sized enterprises (SMEs), and government support for digital financial ecosystems. These factors have collectively made digital lending a powerful tool for economic empowerment and financial inclusion in emerging markets. Consumer protection is a central element, ensuring borrowers have access to clear, understandable loan terms and are shielded from predatory lending practices. Regulations often require lenders to disclose comprehensive information about interest rates, fees, and repayment schedules upfront, promoting transparency and helping borrowers make informed decisions. Additionally, many jurisdictions implement interest rate caps to prevent exorbitant lending rates, ensuring loans remain affordable for consumers. Fee disclosures are similarly mandated, obliging lenders to provide a detailed breakdown of associated costs to avoid hidden charges. Data privacy and security protect sensitive consumer information. Many countries are adopting data protection laws modelled after the General Data Protection Regulation (GDPR) in the EU, which sets stringent standards for collecting, processing, and storing personal data. These regulations require digital lenders to obtain consent from borrowers, limit the use of data for specific purposes, and ensure data accuracy and access controls. Additionally, cybersecurity standards are increasingly emphasised, with regulators mandating security measures to safeguard against cyber threats. This includes encryption, regular security audits, and compliance with international cybersecurity frameworks that protect financial systems from data breaches and fraud. Just like other nations, India also prioritises the privacy and security of individuals’ data. The India Digital Personal Data Protection Act 2023 (DPDPA) that was passed in August 2023 plays a key role in protecting the personal data of an individual. This legislation aims to safeguard the privacy rights of an individual while bringing the focus on responsible data management practices. It focuses on processing of the digital personal data of an individual while giving them the power to protect their personal data. Specific requirements on consent and access to Data Principal rights are cornerstones for DPDPA 2023. Also, huge penalties up to INR 250 Cr are a major deterrent and may ensure compliance once the rules get notified. Licensing and compliance ensure that only authorised and responsible entities operate in the market. Most regulatory bodies require digital lenders to obtain a license, subject to specific criteria such as financial stability, operational transparency, and adherence to consumer protection laws. These licensing requirements prevent fraudulent or unqualified players from entering the market, whereas compliance involves ongoing adherence to regulatory guidelines, including reporting obligations, risk management, and maintaining adequate capital reserves. Enforcement and oversight mechanisms, such as regular audits, inspections, and penalties for non-compliance, are crucial in preserving market integrity. This is how regulatory agencies monitor digital lenders’ activities, ensuring that they follow industry standards, protect consumers, and contribute to a stable financial environment. AML and KYC regulations are essential for maintaining the integrity of digital lending platforms and preventing financial crimes. KYC procedures require digital lenders to verify the identity of borrowers through official documentation, such as government-issued IDs, proof of address, and sometimes biometric data. These measures ensure that lenders only engage with legitimate customers and help mitigate the risks of fraud or illicit activity. AML regulations, on the other hand, focus on detecting and reporting suspicious transactions that may be linked to money laundering. Digital lenders must establish internal systems for monitoring transactions, flagging unusual patterns, and fulfilling reporting obligations to regulatory authorities. One of the primary regulatory challenges is balancing the need for innovation with adequate oversight. While regulators aim to encourage fintech advancements, overly stringent regulations can stifle innovation and limit financial inclusion. Another challenge is regulatory fragmentation, where different regions or countries impose varying standards, creating inconsistencies that complicate cross-border operations for digital lenders. However, this environment also offers significant opportunities for innovation. Governments can develop more adaptive, tech-friendly frameworks that promote growth while ensuring compliance through partnerships between regulators and fintech companies. These collaborations can lead to regulatory sandboxes, where new lending models can be tested in a controlled environment, helping both parties refine policies that support innovation while protecting consumers and maintaining financial stability. Regulation will play a pivotal role in shaping the future of digital lending, determining the balance between fostering innovation and ensuring financial stability. As digital lending continues to evolve, regulatory frameworks will become more critical in promoting transparency, protecting consumers, and mitigating systemic risks. Understanding and navigating these regulatory environments will be essential to the long-term success of digital lenders. Lenders should prioritise compliance by staying informed about regulatory changes, investing in robust data security measures, and adopting transparent lending practices. Engaging proactively with regulators, building strong internal compliance teams, and leveraging partnerships within the fintech ecosystem can help digital lenders meet regulatory requirements and drive innovation safely and sustainably. Step up your startup journey with BHASKAR! From resources to networking, BHASKAR connects Indian innovators with everything they need to succeed. Join today to access a platform built for innovation, growth, and community.Social media users are misrepresenting a report released Thursday by the Justice Department inspector general's office, falsely claiming that it's proof the FBI orchestrated the Capitol riot on Jan. 6, 2021. The watchdog report examined a number of areas, including whether major intelligence failures preceded the riot and whether the FBI in some way provoked the violence. Claims spreading online focus on the report's finding that 26 FBI informants were in Washington for election-related protests on Jan. 6, including three who had been tasked with traveling to the city to report on others who were potentially planning to attend the events. Although 17 of those informants either entered the Capitol or a restricted area around the building during the riot, none of the 26 total informants were authorized to do so by the bureau, according to the report. Nor were they authorized to otherwise break the law or encourage others to do so. Here's a closer look at the facts. CLAIM: A December 2024 report released by the Department of Justice's Office of the Inspector General is proof that the Jan. 6 Capitol riot was a setup by the FBI. THE FACTS: That's false. The report found that no undercover FBI employees were at the riot on Jan. 6 and that none of the bureau's informants were authorized to participate. Informants, also known as confidential human sources, work with the FBI to provide information, but are not on the bureau’s payroll. Undercover agents are employed by the FBI. According to the report, 26 informants were in Washington on Jan. 6 in connection with the day's events. FBI field offices only informed the Washington Field Office or FBI headquarters of five informants that were to be in the field on Jan. 6. Of the total 26 informants, four entered the Capitol during the riot and an additional 13 entered a restricted area around the Capitol. But none were authorized to do so by the FBI, nor were they given permission to break other laws or encourage others to do the same. The remaining nine informants did not engage in any illegal activities. None of the 17 informants who entered the Capitol or surrounding restricted area have been prosecuted, the report says. A footnote states that after reviewing a draft of the report, the U.S. attorney's office in Washington said that it “generally has not charged those individuals whose only crime on January 6, 2021 was to enter restricted grounds surrounding the Capitol, which has resulted in the Office declining to charge hundreds of individuals; and we have treated the CHSs consistent with this approach.” The assistant special agent in charge of the Washington Field Office's counterterrorism division told the inspector general's office that he “denied a request from an FBI office to have an undercover employee engage in investigative activity on January 6.” He, along with then-Washington Field Office Assistant Director in Charge Steven D'Antuono, said that FBI policy prohibits undercover employees at First Amendment-protected events without investigative authority. Many social media users drew false conclusions from the report's findings. “JANUARY 6th WAS A SETUP!" reads one X post that had received more than 11,400 likes and shares as of Friday. “New inspector general report shows that 26 FBI/DOJ confidential sources were in the crowd on January 6th, and some of them went into the Capitol and restricted areas. Is it a coincidence that Wray put in his resignation notice yesterday? TREASON!” The mention of Wray's resignation refers to FBI Director Christopher Wray's announcement Wednesday that he plans to resign at the end of President Joe Biden's term in January. Other users highlighted the fact that there were 26 FBI informants in Washington on Jan. 6, but omitted key information about the findings of the report. These claims echo a fringe conspiracy theory advanced by some Republicans in Congress that the FBI played a role in instigating the events of Jan. 6, 2021, when rioters determined to overturn Republican Donald Trump's 2020 election loss to Democrat Joe Biden stormed the Capitol in a violent clash with police. The report knocks that theory down. Wray called such theories “ludicrous” at a congressional hearing last year. Asked for comment on the false claims spreading online, Stephanie Logan, a spokesperson for the inspector general’s office, pointed The Associated Press to a press release about the report. In addition to its findings about the the FBI's involvement on Jan. 6, the report said that the FBI, in an action its now-deputy director described as a “basic step that was missed,” failed to canvass informants across all 56 of its field offices for any relevant intelligence ahead of time. That was a step, the report concluded, “that could have helped the FBI and its law enforcement partners with their preparations in advance of January 6.” However, it did credit the bureau for preparing for the possibility of violence and for trying to identify known “domestic terrorism subjects” who planned to come to Washington that day. The FBI said in a letter responding to the report that it accepts the inspection general’s recommendation “regarding potential process improvements for future events.” — Find AP Fact Checks here: https://apnews.com/APFactCheck .
John Prescott tributes - 'there was no-one quite like him'
If you have $1,500 to invest in the share market and want exposure to , then it could be worth checking out the two ASX shares in this article. That's because they come highly rated by analysts at Morgans and could generate big returns over the next 12 months. Here's what the broker is saying about them: ( ) While Morgans notes that this ASX oil share has disappointed the market in 2024, it believes that its shares are "trading at deep value levels." As a result, the broker sees it as a good option for investors wanting exposure to this side of the market. It said: New management has had three attempts in 2024 of 'clearing the decks' and resetting a baseline for market expectations. But the numerous downgrades, combined with consistent optimistic messaging, has gradually eroded investor confidence in BPT's ability to execute on its plans and its valuation re-rate as a result. Similar to the market's apparent concerns, we also hold some reservations over short-term execution risks but do view BPT as trading at deep value levels. Investment view: We maintain an ADD rating but continue to caution that patience may be required. Morgans has an add rating and $1.75 price target on Beach Energy's shares. This implies potential upside of 27% for investors from current levels. ( ) Another ASX oil share that could be a no-brainer buy with $1,500 is energy giant Woodside. The broker thinks that the market is undervaluing the company's shares and believes that attractive long-term value is on offer here. It explains: The tide is certainly out in terms of investor sentiment on WDS. Despite Brent oil trading in line with our long-term forecast, WDS' share price implies a near cycle-low oil price level. We do not see this as capable of being explained by WDS' growth profile (comfortably funded) or risks around non-core assets such as Browse. While the share price performance has been disappointing, supported by a strong balance sheet and high margins, we see WDS investors as capable of being patient. Investment view: We maintain an ADD recommendation believing WDS offers attractive long-term value. Morgans currently has an add rating and $33.00 price target on Woodside's shares. This implies potential upside of 37% for investors over the next 12 months. It also expects a very generous ~6% from its shares in FY 2025.
